SCHEMBL2894580

SCHEMBL2894580

O=C(O)c1cc2c(nc1O)CCCCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 1/20 0.48
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 7/20 0.44
SMN1; SMN2 Q16637 6/20 0.44
MAPT P10636 5/20 0.44
LMNA P02545 4/20 0.44
MAPK1 P28482 3/20 0.44
TP53 P04637 2/20 0.44
HTT P42858 2/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SORT1 Q99523 2/20 0.41
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
EEF2K O00418 1/20 0.40
POLB P06746 1/20 0.40
GRM1 Q13255 1/20 0.39
NR2F2 P24468 1/20 0.39
ATM Q13315 1/20 0.39
HSP90AA1 P07900 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30488939 0.98 KDM4E (0.46) SLC9A1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL2902158 0.98 KDM4E (0.46) SLC9A1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL20619534 0.95 KDM4E (0.42) SLC9A1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL30681913 0.95 KDM4E (0.42) SLC9A1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL7910295 0.81 SLC9A1 (0.65) SLC9A1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL31345629 0.81 KDM4E (0.50) SLC9A1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL26617915 0.81 KDM4E (0.50) SLC9A1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL26617630 0.81 KDM4E (0.50) SLC9A1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL10471696 0.81 KDM4E (0.46) SLC9A1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL25281642 0.79 POLB (0.51) SLC9A1KDM4EALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202228-B1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL (JP) 2014-12-10 EP disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME REN, ACE, AGT SLC9A1 395/4885KDM4E 1257/4885ALDH1A1 897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.